Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy United Therapeutics Corporation stock

Learn how to easily invest in United Therapeutics Corporation stock.

United Therapeutics Corporation is a biotechnology business based in the US. United Therapeutics Corporation shares (UTHR) are listed on the NASDAQ and all prices are listed in US Dollars. United Therapeutics Corporation employs 965 staff and has a trailing 12-month revenue of around $1.8 billion.

How to buy shares in United Therapeutics Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – UTHR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

United Therapeutics Corporation stock price (NASDAQ: UTHR)

Use our graph to track the performance of UTHR stocks over time.

United Therapeutics Corporation shares at a glance

Information last updated 2022-09-25.
Latest market close$205.89
52-week range$158.38 - $245.48
50-day moving average $222.27
200-day moving average $205.67
Wall St. target price$248.56
PE ratio 15.7407
Dividend yield $0 (0%)
Earnings per share (TTM) $13.19

Buy United Therapeutics Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 8 of 8
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy United Therapeutics Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

United Therapeutics Corporation price performance over time

Historical closes compared with the close of $205.89 from 2022-09-27

1 week (2022-09-21) 0.16%
1 month (2022-08-26) -4.37%
3 months (2022-06-28) -12.02%
6 months (2022-03-25) 17.76%
1 year (2021-09-28) 9.71%
2 years (2020-09-28) 102.83%
3 years (2019-09-27) 154.69%
5 years (2017-09-28) 73.37%

Is United Therapeutics Corporation stock undervalued or overvalued?

Valuing United Therapeutics Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of United Therapeutics Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

United Therapeutics Corporation's P/E ratio

United Therapeutics Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, United Therapeutics Corporation shares trade at around 16x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

United Therapeutics Corporation's PEG ratio

United Therapeutics Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8291. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into United Therapeutics Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

United Therapeutics Corporation's EBITDA

United Therapeutics Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $939.1 million.

The EBITDA is a measure of a United Therapeutics Corporation's overall financial performance and is widely used to measure a its profitability.

United Therapeutics Corporation financials

Revenue TTM $1.8 billion
Operating margin TTM 49.7%
Gross profit TTM $1.6 billion
Return on assets TTM 10.7%
Return on equity TTM 15.85%
Profit margin 35.27%
Book value $94.93
Market capitalisation $9.5 billion

TTM: trailing 12 months

United Therapeutics Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like United Therapeutics Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

United Therapeutics Corporation's total ESG risk score

Total ESG risk: 35.51

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and United Therapeutics Corporation's overall score of 35.51 (as at 12/31/2018) is nothing to write home about – landing it in it in the 54th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like United Therapeutics Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

United Therapeutics Corporation's environmental score

Environmental score: 6.16/100

United Therapeutics Corporation's environmental score of 6.16 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

United Therapeutics Corporation's social score

Social score: 24.94/100

United Therapeutics Corporation's social score of 24.94 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

United Therapeutics Corporation's governance score

Governance score: 17.41/100

United Therapeutics Corporation's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that United Therapeutics Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

United Therapeutics Corporation's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. United Therapeutics Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that United Therapeutics Corporation has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

United Therapeutics Corporation was last rated for ESG on: 2019-01-01.

Total ESG score 35.51
Total ESG percentile 53.55
Environmental score 6.16
Environmental score percentile 9
Social score 24.94
Social score percentile 9
Governance score 17.41
Governance score percentile 9
Level of controversy 2

United Therapeutics Corporation share dividends

We're not expecting United Therapeutics Corporation to pay a dividend over the next 12 months.

Have United Therapeutics Corporation's shares ever split?

United Therapeutics Corporation's shares were split on a 2:1 basis on 22 September 2009. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your United Therapeutics Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for United Therapeutics Corporation shares which in turn could have impacted United Therapeutics Corporation's share price.

United Therapeutics Corporation share price volatility

Over the last 12 months, United Therapeutics Corporation's shares have ranged in value from as little as $158.38 up to $245.48. A popular way to gauge a stock's volatility is its "beta".

UTHR.US volatility(beta: 0.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while United Therapeutics Corporation's is 0.5358. This would suggest that United Therapeutics Corporation's shares are less volatile than average (for this exchange).

United Therapeutics Corporation overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Frequently asked questions

What percentage of United Therapeutics Corporation is owned by insiders or institutions?
Currently 1.797% of United Therapeutics Corporation shares are held by insiders and 99.552% by institutions.
How many people work for United Therapeutics Corporation?
Latest data suggests 965 work at United Therapeutics Corporation.
When does the fiscal year end for United Therapeutics Corporation?
United Therapeutics Corporation's fiscal year ends in December.
Where is United Therapeutics Corporation based?
United Therapeutics Corporation's address is: 1040 Spring Street, Silver Spring, MD, United States, 20910
What is United Therapeutics Corporation's ISIN number?
United Therapeutics Corporation's international securities identification number is: US91307C1027
What is United Therapeutics Corporation's CUSIP number?
United Therapeutics Corporation's Committee on Uniform Securities Identification Procedures number is: 91307C102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site